Why the study?
To evaluate subclinical atherosclerosis in patients with obesity using arterial stiffness assessed by PWV, CIMT, and biomarkers of endothelial dysfunction including endocan, ADAMTS7, and ADAMTS9.
Is obesity associated with increased subclinical atherosclerosis as measured by arterial stiffness, CIMT, and endothelial dysfunction biomarkers compared to nonobese controls?
Is obesity associated with increased subclinical atherosclerosis as measured by arterial stiffness, CIMT, and endothelial dysfunction biomarkers compared to nonobese controls?
Severe obesity (BMI ≥ 40) is associated with increased arterial stiffness and carotid intima-media thickness, indicating a higher burden of subclinical atherosclerosis.
Severe obesity may signal higher subclinical atherosclerosis burden; hypothesis-generating and should not yet change practice.
Objective: In this study, we aimed to evaluate subclinical atherosclerosis in patients with obesity who had cardiovascular disease risk indicators such as arterial stiffness, which is evaluated using pulse wave velocity (PWV), carotid intima-media thickness (CIMT), and biomarkers of endothelial dysfunction such as endocan, ADAMTS97, and ADAMTS9. Subjects and methods: Sixty obese subjects, including 23 subjects with body mass index (BMI) ≥ 40, 37 subjects with BMI ≥ 30 but < 40, and 60 age-and sex-matched control subjects, were included in our study. Serum endocan, ADAMTS97, and ADAMTS9 levels as well as PWV and CIMT measurements of the subjects in the obese and control groups were performed. Results: In the obesity group, PWV levels were significantly higher than they were in the control group and endocan levels were significantly lower than they were in the control group. When we compared the obese group with BMI ≥ 40 and the control group, the BMI ≥ 40 group had significantly higher PWV and CIMT levels than the control group had, whereas endocan, ADAMTS7, and ADAMTS9 levels were similar to those of the control group. When we compared the obese group with BMI ≥ 30 < 40 to the control group, endocan levels were lower in the group with BMI ≥30 < 40, and PWV and CIMT levels were similar to the control group. Conclusion: We found that arterial stiffness and CIMT increased in obese patients with BMI ≥ 40 and that increased arterial stiffness was associated with age, systolic blood pressure, and HBA1C. In addition, we found that the endocan levels were lower in obese patients than they were in nonobese control individuals.
No takes yet. Share an insight, caveat, or question.
Can et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: